北京万东医疗科技股份有限公司（以下简称"公司"）第十届董事会 第十二次会议于 2026 年 1 月 9 日以通讯表决方式召开。本次会议的会议通 知及相关资料于 2026 年 1 月 5 日以电子邮件的方式向全体董事发出。会议 应到董事 8 人，实到 8 人，公司高管人员列席会议。本次会议的召开符合 《公司法》和《公司章程》的规定，所作决议合法有效。 依据《公司章程》规定，会议由董事长马赤兵先生主持，形成如下决 议： 一、 审议通过《关于提名非独立董事的议案》。 根据《股票上市规则》和《公司章程》的规定以及公司经营发展需要， 经公司董事会提名委员会审核通过，公司董事会同意提名王建国为公司第 十届董事会非独立董事（简历附后），任期自股东会审议通过之日起至本届 董事会届满。 本议案表决结果：同意 8 票，反对 0 票，弃权 0 票。 证券代码：600055 证券简称：万东医疗 编号：临 2026-002 北京万东医疗科技股份有限公司 第十届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 本议案须提交股东 ...

Group 1 - The core viewpoint of the article is the official release and implementation of two group standards, T/CAMDI163—2025 and T/CAMDI164—2025, led by Wandong Medical, a subsidiary of Midea Medical [1] - These standards focus on the core components of full-field DR equipment, detailing technical requirements, testing methods, product classification, and inspection standards [1] - The implementation of these standards addresses the long-standing lack of unified technical specifications in the field, providing a scientific basis and action guide for the entire design, production, and inspection chain [1] Group 2 - The new standards align closely with clinical needs and the current state of industry development, promoting a transition from "spontaneous exploration" to a "standard-led" high-quality development model in the relevant industry [1]

Group 1 - Company Wandong Medical announced on January 5 that it has repurchased approximately 1.8 million shares through centralized bidding, accounting for 0.2564% of the total share capital [1] - The highest purchase price for the repurchased shares was 17.99 yuan per share, while the lowest was 15.71 yuan per share [1] - The total amount spent on the share repurchase was approximately 29.99 million yuan [1] Group 2 - The iMoutai App saw a surge in popularity, reaching the top of the Apple shopping chart, with 100,000 users placing orders for the product priced at 1499 yuan [1] - The rapid sellout of 1,000 boxes of Moutai was attributed to the same pricing strategy employed by distributors as a promotional effort [1]

证券代码：600055 证券简称：万东医疗 公告编号：临 2026-001 北京万东医疗科技股份有限公司 关于股份回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2026 年 1 月 5 日，公司通过集中竞价交易方式累计回购股份 1,802,700 股，已回购股份占公司总股本的比例为 0.2564%，购买的最高价为 17.99 元/股、最低价为 15.71 元/股，已支付的总金额为 29,992,822.08 元（不 含交易费用）。本次回购股份符合相关法律法规的规定和回购股份方案的要求。 三、 其他事项 | 回购方案首次披露日 | 2025/8/23 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 日~2026 2025 8 | 22 | 年 8 | 月 | 日 21 | | 预计回购金额 | 万元 3,000 万元~6,000 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600055 证券简称：万东医疗 公告编号：临 2026-001 北京万东医疗科技股份有限公司 关于股份回购进展的公告 重要内容提示： | 回购方案首次披露日 | 2025/8/23 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 8 月 8 月 21 | 22 | 日~2026 | 年 | 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 1,802,700股 | | | | | | 累计已回购股数占总股本比例 | 0.2564% | | | | | | 累计已回购金额 | 29,992,822.08元 | | | | | | 实际回购价格 ...

格隆汇1月5日丨万东医疗(600055.SH)公布，截至2025年1月5日，公司通过集中竞价交易方式累计回购 股份180.27万股，已回购股份占公司总股本的比例为0.2564%，购买的最高价为17.99元/股、最低价为 15.71元/股，已支付的总金额为2999.28万元（不含交易费用）。 ...

华宝中证医疗ETF（512170）基金经理为胡洁。 1月5日，万东医疗涨5.39%，截至发稿，报16.42元/股，成交1.53亿元，换手率1.35%，总市值115.44亿 元。 资料显示，北京万东医疗科技股份有限公司位于北京市朝阳区酒仙桥东路9号院3号楼，成立日期1997年 5月12日，上市日期1997年5月19日，公司主营业务涉及从事影像类医疗器械的研发、制造、销售及影像 诊断服务。主营业务收入构成为：医疗器械销售业务90.72%，医疗服务及其他5.66%，其他(补 充)3.62%。 从万东医疗十大流通股东角度 数据显示，华宝基金旗下1只基金位居万东医疗十大流通股东。华宝中证医疗ETF（512170）三季度减 持209.86万股，持有股数1191.98万股，占流通股的比例为1.7%。根据测算，今日浮盈赚取约1001.26万 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模264.04亿。今年以来收益3.89%，同类 排名3822/4189；近一年收益3.89%，同类排名3822/4189；成立以来收益1.8%。 截至发稿，胡洁累计任职时间13年85天，现任基金资产总规模1002 ...

本报讯(记者王镜茹)我国无液氦超导磁共振技术研发与应用取得重要进展。 据悉，该技术是目前全球唯一实现规模化装机应用的100%无液氦超导磁共振产品，已在亚洲、欧洲、 非洲等近20个国家成功投入临床使用。 万东医疗作为技术研发与产业化的主体，与北京积水潭医院联合，辐射全国多区域医疗中心，开展多中 心、大样本临床研究，推动技术持续优化与标准化应用。通过AI辅助诊断、智能后处理流程与高性能 硬件平台的深度融合，不仅提升了诊断精准性与效率，也助力基层医疗机构开展高质量影像检查，让先 进技术更可及、更普惠。 超导磁共振是医学影像诊断的核心装备，其运行长期依赖液氦维持超低温环境。攻克无液氦技术，成为 全球行业共同面临的重要课题。 万东医疗通过系统性自主研发，在全球率先实现无液氦超导磁共振技术的突破和产品上市，从源头上摆 脱了对液氦资源的依赖，完成了液氦"从有到无"的革命，为行业发展提供了切实可行的中国方案。 近日，由美的集团（000333）股份有限公司旗下北京万东医疗（600055）科技股份有限公司(以下简 称"万东医疗")与北京积水潭医院共同牵头的"无液氦超导磁共振系统"项目，成功入选中华人民共和国 工业和信息化部、国家 ...

Core Viewpoint - The article discusses the increasing trend of companies voluntarily abandoning bids for medical equipment procurement projects in China, highlighting the complexities and challenges within the industry, including price competition and regulatory issues [2][12]. Group 1: Bid Abandonment Cases - In 2025, there has been a noticeable increase in cases of companies voluntarily abandoning bids in the medical equipment sector, with notable examples including GE Healthcare abandoning a bid just three days after winning [2][9]. - The case of WanDong Medical, which won a bid for a 1.5T MRI system at a price of 4 million yuan, is particularly striking as the company later chose to abandon the bid after a lengthy and complicated procurement process [4][12]. - The article notes that this year marks the fifth case of a medical equipment manufacturer abandoning a bid, indicating a troubling trend in the industry [9][12]. Group 2: Reasons for Bid Abandonment - Common reasons for voluntary bid abandonment include underestimating production capacity before bidding and discovering that the actual profit margins do not meet expectations after winning the bid [13][14]. - The practice of aggressive price competition, where companies submit low bids to win contracts, often leads to situations where the awarded price is unsustainable for project operation, prompting companies to abandon the bid [13][14]. - High-priced bids may also be abandoned if hospitals express concerns about the pricing, potentially leading to discussions that result in the company voluntarily withdrawing [13][14]. Group 3: Industry Dynamics and Challenges - The medical equipment procurement landscape has shifted towards centralized purchasing, which has significantly reduced costs but has also intensified price competition among manufacturers [20][21]. - The article highlights that the current environment is characterized by high inventory levels and a price war among manufacturers, which has led to declining revenues and profits for leading medical device companies [20][21]. - Regulatory bodies are taking action to address issues of price competition, with recent announcements aimed at maintaining fair market practices and preventing below-cost bidding [21].

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.65倍，行业中值38.17倍，万东医疗排 名第123位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13万东医疗771.0070.602.37111.08亿行业平均 50.6552.834.43108.44亿行业中值38.1738.932.6252.73亿1九安医疗9.9211.230.84187.41亿2康德莱 15.1617.161.3936.95亿3奥美医疗15.5719.101.8970.42亿4英科医疗15.9918.571.50272.16亿5维力医疗 16.0617.882.0339.23亿6奥泰生物16.9316.491.2849.89亿7山东药玻17.4014.121.63133.12亿8安杰思 17.4716.251.9247.68亿9新华医疗17.5112.891.1389.12亿10九强生物18.2914.832.0778.98亿11安图生物 18.4716.972.32202.74亿12三鑫医疗18.9920.413.3646.41亿 股东方面，截至2025年9月30日，万东医疗股东户数27164户，较上次增加3 ...